The role of the PAX8/PPARγ fusion oncogene in thyroid cancer

Kimberly A. Placzkowski, Honey V. Reddi, S. K G Grebe, Norman L. Eberhardt, Bryan McIver

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPAR γ translocation in follicular thyroid carcinoma has promoted progress in the role of PPAR γ as a tumor suppressor and potential therapeutic target. The PAX8/PPAR γ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPAR γ, and stimulates transcription of PAX8-responsive promoters. PPAR γ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.

Original languageEnglish (US)
Article number672829
JournalPPAR Research
DOIs
StatePublished - 2008

Fingerprint

Oncogene Fusion
Peroxisome Proliferator-Activated Receptors
Thyroid Neoplasms
Follicular Adenocarcinoma
Mortality
Gene Fusion
Oncogenes
Molecular Biology
Carcinoma
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Drug Discovery

Cite this

Placzkowski, K. A., Reddi, H. V., Grebe, S. K. G., Eberhardt, N. L., & McIver, B. (2008). The role of the PAX8/PPARγ fusion oncogene in thyroid cancer. PPAR Research, [672829]. https://doi.org/10.1155/2008/672829

The role of the PAX8/PPARγ fusion oncogene in thyroid cancer. / Placzkowski, Kimberly A.; Reddi, Honey V.; Grebe, S. K G; Eberhardt, Norman L.; McIver, Bryan.

In: PPAR Research, 2008.

Research output: Contribution to journalArticle

Placzkowski, KA, Reddi, HV, Grebe, SKG, Eberhardt, NL & McIver, B 2008, 'The role of the PAX8/PPARγ fusion oncogene in thyroid cancer', PPAR Research. https://doi.org/10.1155/2008/672829
Placzkowski KA, Reddi HV, Grebe SKG, Eberhardt NL, McIver B. The role of the PAX8/PPARγ fusion oncogene in thyroid cancer. PPAR Research. 2008. 672829. https://doi.org/10.1155/2008/672829
Placzkowski, Kimberly A. ; Reddi, Honey V. ; Grebe, S. K G ; Eberhardt, Norman L. ; McIver, Bryan. / The role of the PAX8/PPARγ fusion oncogene in thyroid cancer. In: PPAR Research. 2008.
@article{bc18043d85604af484ee0d419b2321d5,
title = "The role of the PAX8/PPARγ fusion oncogene in thyroid cancer",
abstract = "Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPAR γ translocation in follicular thyroid carcinoma has promoted progress in the role of PPAR γ as a tumor suppressor and potential therapeutic target. The PAX8/PPAR γ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPAR γ, and stimulates transcription of PAX8-responsive promoters. PPAR γ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.",
author = "Placzkowski, {Kimberly A.} and Reddi, {Honey V.} and Grebe, {S. K G} and Eberhardt, {Norman L.} and Bryan McIver",
year = "2008",
doi = "10.1155/2008/672829",
language = "English (US)",
journal = "PPAR Research",
issn = "1687-4757",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The role of the PAX8/PPARγ fusion oncogene in thyroid cancer

AU - Placzkowski, Kimberly A.

AU - Reddi, Honey V.

AU - Grebe, S. K G

AU - Eberhardt, Norman L.

AU - McIver, Bryan

PY - 2008

Y1 - 2008

N2 - Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPAR γ translocation in follicular thyroid carcinoma has promoted progress in the role of PPAR γ as a tumor suppressor and potential therapeutic target. The PAX8/PPAR γ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPAR γ, and stimulates transcription of PAX8-responsive promoters. PPAR γ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.

AB - Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPAR γ translocation in follicular thyroid carcinoma has promoted progress in the role of PPAR γ as a tumor suppressor and potential therapeutic target. The PAX8/PPAR γ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPAR γ, and stimulates transcription of PAX8-responsive promoters. PPAR γ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.

UR - http://www.scopus.com/inward/record.url?scp=55949130900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949130900&partnerID=8YFLogxK

U2 - 10.1155/2008/672829

DO - 10.1155/2008/672829

M3 - Article

JO - PPAR Research

JF - PPAR Research

SN - 1687-4757

M1 - 672829

ER -